Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China · Delayed Price · Currency is CNY 8.18
-0.03 (-0.37%)
Aug 26, 2026, 3:00 PM CST
SHA:600664 Revenue
Harbin Pharmaceutical Group had revenue of 4.18B CNY in the quarter ending March 31, 2026, with 0.02% growth. This brings the company's revenue in the last twelve months to 15.96B, down -1.50% year-over-year. In the year 2025, Harbin Pharmaceutical Group had annual revenue of 15.96B, down -1.31%.
Revenue (ttm)
15.96B
Revenue Growth
-1.50%
P/S Ratio
1.30
Revenue / Employee
1.59M
Employees
10,039
Market Cap
20.68B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.96B | -211.79M | -1.31% |
| Dec 31, 2024 | 16.18B | 719.28M | 4.65% |
| Dec 31, 2023 | 15.46B | 1.65B | 11.93% |
| Dec 31, 2022 | 13.81B | 1.01B | 7.86% |
| Dec 31, 2021 | 12.80B | 2.01B | 18.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Livzon Pharmaceutical Group | 10.75B |
| Tasly Pharmaceutical Group | 8.15B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.12B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
| Kangmei Pharmaceutical | 4.97B |
| Chengdu Kanghong Pharmaceutical Group | 4.31B |
| Betta Pharmaceuticals | 3.85B |
| Shanghai Haoyuan Chemexpress | 3.00B |
Harbin Pharmaceutical Group News
- 5 weeks ago - Why buyout funds, not IPOs, may define China’s next capital market cycle: Zhang Yichen - South China Morning Post
- 5 weeks ago - Citic Capital CEO on making China a financial powerhouse - South China Morning Post